Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

Although new U.S. tariffs on Canada, Mexico, and China are putting pressure on markets, investors are shifting toward ...

Bristol-Myers Squibb Company (NYSE:BMY) 45th Annual TD Cowen Health Care Conference March 4, 2025 2:30 PM ETCompany ParticipantsAdam Lenkowsky - ...

Welcome to Medicare Part D, where your prescription drugs come with co-pays and co-insurance. If you thought co-pays and ...

Shares of Pfizer (NYSE: PFE), and UnitedHealth Group (NYSE: UNH) have been beaten down to near 52-week lows. Shares of Pfizer ...

There are many ways to make money on Wall Street, but some methods are a lot more reliable than others. Whether you're ...

Kathy Davis of Canonsburg underwent heart surgery, but complications left her with right heart failure, a condition where the ...

A new study from the USC Schaeffer Center shows that out-of-pocket costs for brand-name medications have increased sharply ...

Expected out-of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read why PFE stock is a Sell.

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it selected for negotiation.